Tacrolimus in transplant rejection

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 1, 2013, Pages 115-122

  Rath, Thomas ^a  

^a Westpfalz Klinikum GmbH   (Germany)

Author keywords

Rejection; Renal transplantation; Review; Tacrolimus

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; TACROLIMUS;

ADD ON THERAPY; ANEMIA; DIABETES MELLITUS; DIARRHEA; DRUG ADSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DYSPEPSIA; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HUMAN; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NEPHROTOXICITY; NEUROTOXICITY; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREMOR; VOMITING;

CYCLOSPORINE; DIABETES MELLITUS; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TACROLIMUS; TREATMENT OUTCOME;

EID: 84871558375     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.751374     Document Type: Review

References (75)

1. Starzl TE, Todo S, Fung J, et al. FK 506 for liver, kidney, and pancreas transplantation. Lancet 1989;2:1000-4 (Pubitemid 19257914)
2. Todo S, Fung JJ, Tzakis A, et al. One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc 1991;23:1397-402
3. Armitage JM, Kormos RL, Fung J, Starzl TE. The clinical trial of FK 506 as primary and rescue immunosuppression in adult cardiac transplantation. Transplant Proc 1991;23:3054-7
4. Jensen CW, Jordan ML, Schneck FX, et al. Pediatric renal transplantation under FK 506 immunosuppression. Transplant Proc 1991;23:3075-7
5. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994;344:423-8
6. The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994;331:1110-15
7. FDA approved new drug bulletin: aprotinin injection (trasylol), tacrolimus (prograf). RN 1994;57:31-4
8. Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant 2006;6:1111-31
9. Wlodarczyk Z, Squifflet JP, Ostrowski M, et al. Pharmacokinetics for once-versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. Am J Transplant 2009;9:2505-13
10. Cabello M, Garcia P, Gonzalez-Molina M, et al. Pharmacokinetics of once-versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. Transplant Proc 2010;42:3038-40
11. van Hooff J, Van der Walt I, Kallmeyer J, et al. Pharmacokinetics in stable kidney transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations. Ther Drug Monit 2012;34:46-52
12. Alloway R, Vanhaecke J, Yonan N, et al. Pharmacokinetics in stable heart transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations. J Heart Lung Transplant 2011;30:1003-10
13. Zhang YF, Chen XY, Dai XJ, et al. Pharmacokinetics of tacrolimus converted from twice-daily formulation to once-daily formulation in Chinese stable liver transplant recipients. Acta Pharmacol Sin 2011;32:1419-23
14. Lang P, Baron C. Molecular mechanisms of immunosuppressive chemical agents recently introduced in clinical transplantation protocols. Nephrol Dial Transplant 1997;12:2050-4 (Pubitemid 27423238)
15. Gruber SA, Hewitt JM, Sorenson AL, et al. Pharmacokinetics of FK506 after intravenous and oral administration in patients awaiting renal transplantation. J Clin Pharmacol 1994;34:859-64 (Pubitemid 24325015)
16. Ihara H, Shinkuma D, Ichikawa Y, et al. Intra-and interindividual variation in the pharmacokinetics of tacrolimus (FK506) in kidney transplant recipients-importance of trough level as a practical indicator. Int J Urol 1995;2:151-5
17. Filler G, Grygas R, Mai I, et al. Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants. Nephrol Dial Transplant 1997;12:1668-71 (Pubitemid 27346294)
18. Filler G, Zimmering M, Mai I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol 2000;14:100-4 (Pubitemid 30085288)
19. Anglicheau D, Verstuyft C, Laurent-Puig P, et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 2003;14:1889-96 (Pubitemid 36750485)
20. Zhang X, Liu ZH, Zheng JM, et al. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation. Clin Transplant 2005;19:638-43 (Pubitemid 41341696)
21. Sato K, Amada N, Sato T, et al. Severe elevations of FK506 blood concentration due to diarrhea in renal transplant recipients. Clin Transplant 2004;18:585-90 (Pubitemid 39264359)
22. Starzl TE, Fung J, Jordan M, et al. Kidney transplantation under FK 506. JAMA 1990;264:63-7 (Pubitemid 20209172)
23. Japanese FK 506 Study Group. Two-year follow-up study of the efficacy and safety of FK 506 in kidney transplant patients. Transpl Int 1994;7(Suppl 1):S247-51
24. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation 1995;59:485-90
25. Laskow DA, Vincenti F, Neylan JF, et al. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation 1996;62:900-5 (Pubitemid 26360348)
26. Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997;63:977-83 (Pubitemid 27173021)
27. Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997;64:436-43 (Pubitemid 27349884)
28. Johnson C, Ahsan N, Gonwa T, et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000;69:834-41 (Pubitemid 30174107)
29. Ahsan N, Johnson C, Gonwa T, et al. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years. Transplantation 2001;72:245-50 (Pubitemid 32729343)
30. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial to compare tacrolimus and prednisone with and without mycophenolate mofetil in patients undergoing renal transplantation: first report. J Urol 1998;160:1982-5
31. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. Transplantation 1999;67:411-15 (Pubitemid 29094012)
32. Knoll GA, Bell RC. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. BMJ 1999;318:1104-7 (Pubitemid 29192148)
33. Webster A, Woodroffe RC, Taylor RS, et al. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2005;CD003961
34. Yao G, Albon E, Adi Y, et al. A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children. Health Technol Assess 2006;10:iii-xi.1
35. Hauser IA, Neumayer HN. Tacrolimus and cyclosporine efficacy in high-risk kidney transplantation. European Multicentre Tacrolimus (FK506) Renal Study Group. Transpl Int 1998;11(Suppl 1):S73-7 (Pubitemid 128683511)
36. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357:2562-75 (Pubitemid 350294223)
37. Armitage JM, Fricker FJ, del Nido P, et al. The clinical trial of FK 506 as primary and rescue immunosuppression in pediatric cardiac transplantation. Transplant Proc 1991;23:3058-60
38. Klintmalm GB, Goldstein R, Gonwa T, et al. Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group. Transplant Proc 1993;25:679-88 (Pubitemid 23082515)
39. Burke GW, Alejandro R, Ciancio G, et al. The use of FK506 in simultaneous pancreas/kidney transplantation: rescue, induction, and maintenance immunosuppression. Transplant Proc 1995;27:3123-4 (Pubitemid 26016100)
40. Gruessner RW, Burke GW, Stratta R, et al. A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. Transplantation 1996;61:261-73 (Pubitemid 26044542)
41. Mentzer RM Jr, Jahania MS, Lasley RD. Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. The U.S. Multicenter FK506 Study Group. Transplantation 1998;65:109-13 (Pubitemid 28100441)
42. Felldin M, Backman L, Brattstrom C, et al. Rescue therapy with tacrolimus (FK 506) in renal transplant recipients-a Scandinavian multicenter analysis. Transpl Int 1997;10:13-18 (Pubitemid 26413385)
43. Witzke O, Becker G, Erhard J, et al. Tacrolimus rescue therapy in patients with rejection and long-term dialysis after kidney transplantation. Clin Nephrol 1998;49:24-7 (Pubitemid 28043363)
44. Budde K, Fritsche L, Mai I, et al. Clinical pharmacokinetics of tacrolimus in rescue therapy after renal transplantation. Int J Clin Pharmacol Ther 1996;34:493-7 (Pubitemid 26386035)
45. Hymes LC, Warshaw BL. Tacrolimus rescue therapy for children with acute renal transplant rejection. Pediatr Nephrol 2001;16:990-2 (Pubitemid 34026708)
46. Herget S, Heemann U, Friedrich J, et al. Initial experience with tacrolimus rescue therapy in OKT3 resistant rejection. Clin Nephrol 1996;45:352-4 (Pubitemid 26150771)
47. Woodle ES, Thistlethwaite JR, Gordon JH, et al. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. Transplantation 1996;62:594-9 (Pubitemid 26313900)
48. Jordan ML, Naraghi R, Shapiro R, et al. Tacrolimus rescue therapy for renal allograft rejection-five-year experience. Transplantation 1997;63:223-8 (Pubitemid 27121202)
49. Pascual M, Saidman S, Tolkoff-Rubin N, et al. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation 1998;66:1460-4 (Pubitemid 29014024)
50. Liu M, Ji SM, Tang Z, et al. C4d-positive acute humoral renal allograft rejection: rescue therapy by immunoadsorption in combination with tacrolimus and mycophenolate mofetil. Transplant Proc 2004;36:2101-3 (Pubitemid 39424340)
51. Ji SM, Liu ZH, Chen JS, et al. Rescue therapy by immunoadsorption in combination with tacrolimus and mycophenolate mofetil for C4d-positive acute humoral renal allograft rejection. Transplant Proc 2006;38:3459-63
52. Schwarz C, Regele H, Huttary N, et al. Rescue therapy with tacrolimus and mycophenolate mofetil does not prevent deterioration of graft function in C4d-positive chronic allograft nephropathy. Wien Klin Wochenschr 2006;118:397-404
53. Borrows R, Loucaidou M, Van TJ, et al. Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation. Am J Transplant 2004;4:1845-51 (Pubitemid 39434446)
54. Borrows R, Loucaidou M, Van Tromp J, et al. Steroid sparing in renal transplantation with tacrolimus and mycophenolate mofetil: three-year results. Transplant Proc 2005;37:1792-4 (Pubitemid 40790833)
55. Ellis D. Growth and renal function after steroid-free tacrolimus-based immunosuppression in children with renal transplants. Pediatr Nephrol 2000;14:689-94 (Pubitemid 30394454)
56. Freise CE, Kang SM, Feng S, et al. Excellent short-term results with steroid-free maintenance immunosuppression in low-risk simultaneous pancreas-kidney transplantation. Arch Surg 2003;138:1121-5
57. Ringe B, Braun F, Schutz E, et al. A novel management strategy of steroid-free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil. Transplantation 2001;71:508-15 (Pubitemid 32207201)
58. Rostaing L, Cantarovich D, Mourad G, et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 2005;79:807-14 (Pubitemid 40546200)
59. Vitko S, Klinger M, Salmela K, et al. Two corticosteroid-free regimenstacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: results of the Atlas study. Transplantation 2005;80:1734-41 (Pubitemid 43053999)
60. Kramer BK, Klinger M, Vitko S, et al. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial. Transplantation 2012;published online; doi:10.1097/TP.0b013e31825c1d6c [doi]
61. Shapiro R, Fung JJ, Jain AB, et al. The side effects of FK 506 in humans. Transplant Proc 1990;22:35-6 (Pubitemid 20112747)
62. Asante-Korang A, Boyle GJ, Webber SA, et al. Experience of FK506 immune suppression in pediatric heart transplantation: a study of long-term adverse effects. J Heart Lung Transplant 1996;15:415-22 (Pubitemid 26144514)
63. Bulatova N, Yousef AM, Al-Khayyat G, Qosa H. Adverse effects of tacrolimus in renal transplant patients from living donors. Curr Drug Saf 2011;6:3-11
64. McCauley J, Takaya S, Fung J, et al. The question of FK 506 nephrotoxicity after liver transplantation. Transplant Proc 1991;23:1444-7
65. Katari SR, Magnone M, Shapiro R, et al. Clinical features of acute reversible tacrolimus (FK 506) nephrotoxicity in kidney transplant recipients. Clin Transplant 1997;11:237-42 (Pubitemid 27230804)
66. Olyaei AJ, de Mattos AM, Bennett WM. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr Opin Crit Care 2001;7:384-9 (Pubitemid 34020400)
67. Friemann S, Feuring E, Padberg W, Ernst W. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus. Transplant Proc 1998;30:1240-2 (Pubitemid 28309556)
68. Hariharan S, Munda R, Cavallo T, et al. Rescue therapy with tacrolimus after combined kidney/pancreas and isolated pancreas transplantation in patients with severe cyclosporine nephrotoxicity. Transplantation 1996;61:1161-5 (Pubitemid 26134763)
69. Odocha O, McCauley J, Scantlebury V, et al. Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression. Transplant Proc 1993;25:2433-4 (Pubitemid 23239489)
70. Tanabe K, Koga S, Takahashi K, et al. Diabetes mellitus after renal transplantation under FK 506 (tacrolimus) as primary immunosuppression. Transplant Proc 1996;28:1304-5 (Pubitemid 26195212)
71. Gnatta D, Keitel E, Heineck I, et al. Use of tacrolimus and the development of posttransplant diabetes mellitus: a Brazilian single-center, observational study. Transplant Proc 2010;42:475-8
72. Kuypers DR, Claes K, Bammens B, et al. Early clinical assessment of glucose metabolism in renal allograft recipients: diagnosis and prediction of post-transplant diabetes mellitus (PTDM). Nephrol Dial Transplant 2008;23:2033-42 (Pubitemid 351768147)
73. Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007;7:1506-14 (Pubitemid 46776239)
74. Chadban S. New-onset diabetes after transplantation-should it be a factor in choosing an immunosuppressant regimen for kidney transplant recipients. Nephrol Dial Transplant 2008;23:1816-18 (Pubitemid 351768173)
75. Ekberg H, Bernasconi C, Noldeke J, et al. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. Nephrol Dial Transplant 2010;25:2004-10